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Abstract
Background: Clinical practice guidelines are systematically developed statements designed to
assist in patient and physician clinical decision making for specific clinical circumstances. In order to
establish which guideline topics are priorities, practitioners were surveyed regarding their current
practice.
Methods: One hundred ninety-seven practitioners in Ontario, Canada were mailed a survey
exploring their current practice or opinion regarding the prophylactic use of anticonvulsant drugs
in patients with malignant glioma who had never had a seizure. The survey consisted of seven
questions regarding the relevance of a guideline on the subject to the practitioner's practice, the
proportion of clinical cases involving anticonvulsant use, knowledge of existing guidelines on this
topic, interest in reviewing a completed practice guideline and three clinical scenarios.
Results: There were 122 respondents who returned the survey (62% rate of return). Eighty
percent of the practitioners who responded indicated that less than 25% of their clinical cases
involved the use of anticonvulsants; however, only 16% of respondents indicated that a practice
guideline would be irrelevant to their practice. Eighty percent of respondents volunteered to
review a draft version of a practice guideline on the use of anticonvulsants. The survey presented
the practitioners with three scenarios where anticonvulsants in patients with brain tumours may
be appropriate: peri-operatively in patients without seizures, postoperatively in patients currently
using anticonvulsants, and thirdly in patients not currently using anticonvulsants or undergoing
surgery. In contrast to the third situation, the first two situations yielded considerable variation in
practitioner response.
Conclusion: The survey established that there is some variation present in the current practice
of anticonvulsant use in the patients with brain tumours. Whether there is an optimal treatment
practice has yet to be determined. Practitioners do seem to feel that a guideline on anticonvulsant
use in warranted, and most practitioners would be interested in being part of the guideline
development process.
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Background
Clinical practice guidelines are systematically developed
statements designed to assist in patient and physician
clinical decision making for specific clinical circumstances
[1]. They can also be used to inform policy decisions [2].
The steps involved in developing evidence-based clinical
practice guidelines include the identification of clinical
problems, synthesis of the evidence, formulation of rec-
ommendations, independent review of the guideline, dis-
semination of the guideline, and maintenance of the
guideline [3]. Choosing a guideline topic entails careful
consideration of various issues. The Agency for Healthcare
Research and Quality (AHRQ) has developed a list of six
factors that should be considered when selecting a guide-
line topic: the potential of a guideline to reduce unwanted
variation in practice, the prevalence of a specific illness,
the adequacy of the evidence that informs recommenda-
tions, the amenability of a condition to prevention or
treatment, the needs of a special population group, and
costs [4]. Others have also identified likelihood to influ-
ence change in practice, relevance, burden of illness, and
the potential for significant benefit and harm as factors to
consider when selecting a guideline topic [3].
Prior to the development of a clinical practice guideline,
an environmental scan or preliminary practice survey of
practitioners who are the intended audience can serve
many purposes. Data can be collected on clinicians'
reported practice in a given field, their opinions on the rel-
evance and need for a guideline on a particular topic, and
their knowledge of existing evidence sources or guidelines
that could be incorporated into the guideline develop-
ment process. The survey can help prioritize potential
guideline topics and aid in choosing a topic that could
potentially have the greatest impact. In addition, evidence
indicates that participation by practitioners in the process
is linked to positive attitudes towards the guidelines and
potentially influences the extent to which they integrate
the final recommendations into their practice [5].
The purpose of this study was to conduct a pre-guideline
practice survey of relevant clinicians on the use of prophy-
lactic anticonvulsant drugs in patients with brain
tumours. Our intent was to assess self-reports of clini-
cians' current use of anticonvulsant drugs for this patient
population, their perceptions of the need for clinical prac-
tice guidelines on the use of anticonvulsants, feedback
regarding their knowledge of existing guidelines, and their
interest in participating in the guideline process as an
external reviewer.
Methods
Context
The Practice Guidelines Initiative of Cancer Care Ontario's
Program in Evidence-based Care provides context for this
study. The Initiative's core activity is the development of
cancer practice guidelines by multidisciplinary guideline
panels, disease site groups (DSGs), using the methodol-
ogy of the Practice Guidelines Development Cycle [3].
Recently, the Neuro-oncology DSG identified the use of
prophylactic anticonvulsant drugs in patients with brain
tumours as a potential guideline topic. During discussions
on whether to pursue this topic, members of the DSG
reflected on their perceptions of the clinical use of these
drugs. Practitioners sometimes administer prophylactic
anticonvulsant drugs to patients with brain tumours to
prevent an initial seizure, because these drugs are used to
manage patients who have a history of seizures. Practi-
tioners also commonly use prophylactic anticonvulsant
drugs for similar clinical situations: for example, in the
peri-operative period following craniotomy or after closed
head injury. Neurosurgeons are, therefore, familiar with
the use of prophylactic anticonvulsant drugs, and some
extend this use to patients with newly diagnosed brain
tumours, despite the lack of evidence favouring such a
practice. The concern with prescribing prophylactic anti-
convulsant drugs is that there are several adverse effects
associated with these drugs, including cognitive impair-
ment, liver damage, and skin rashes.
Before the Neuro-oncology DSG developed the guideline,
members decided to conduct a practice survey of their
intended audience, Ontario clinicians, to determine if
there was support in the practicing community for this
topic and if their perceptions of use of this drug were sup-
ported.
Participants
Practitioners who managed patients with neurological
diagnoses were eligible to participate in the study. One
hundred ninety-seven practitioners were identified
through a database of the Practice Guideline Initiative that
provides information on clinicians and details of their
clinical practice. Practitioners are eligible to be included
on the database if they practice in Ontario, Canada and
treat patients with cancer. The database includes informa-
tion regarding the specific occupation of the practitioners
(medical oncologist, radiation oncologist, surgeon, etc.),
the specialty of the practitioner (neurology, hematology,
etc.) and the location of practice (regional cancer centre,
community or private medical office).
Procedure
The practitioners selected from the database were sent a
letter describing the purpose of the survey, the survey, and
a self-addressed postage-paid envelope in which to return
the survey. The practitioners were given the option of
either faxing or mailing the survey back to the researchers.
To maximize response rate, a modified Dillman tech-
nique [6] was used. Two weeks after the first survey pack-BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/23
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age was sent, practitioners who had not responded were
sent a postcard to remind them of the survey. Two weeks
after the postcards were sent, the survey, another letter
describing the purpose of the survey, and a self-addressed
postage-paid envelope were sent to the practitioners who
still had not responded.
Survey
The survey consisted of seven questions. Three questions
focused on the relevance of the potential guideline topics
to the respondents' clinical practice (5-point scale: very
relevant to very irrelevant); the proportion of their prac-
tice related to the targeted clinical conditions (<25%, 26–
50%, 51–75% and 76%+); and knowledge of existing
guidelines on these topics (open question). Respondents
were then presented with three clinical scenarios:
1. In patients who have never had seizures, when are peri-
operative anticonvulsant medications indicated? There
was a 5-point likert scale to measure response for this
question, ranging from "always" to "never".
2. An otherwise healthy 58 year old woman is found to
have an enhancing right frontal lobe mass on a CT scan
ordered for headaches. There is no history seizures. A
craniotomy for excision of a suspected malignant glioma
is planned. After successful surgery the pathology returns
as a malignant glioma (GBM). The patient is planned for
and starts external beam radiotherapy. Assume the patient
was treated with anticonvulsant medications pre-opera-
tively and is free of anticonvulsant drug side effects and is
seizure-free. There were five choices for this question: "I
recommend that patients remain on anticonvulsants"; "I
recommend that patients taper and discontinue the anti-
convulsants"; "I discuss the benefits and risks of anticon-
vulsants with the patient and let him or her decide what
to do"; "other"; or "I do not encounter this clinical situa-
tion".
3. A 58 year old woman with known lung cancer develops
multiple supratentorial brain metastases. No surgery is
planned. There is no history of seizures. There were five
choices for this question: "I recommend prophylactic
anticonvulsants in this situation"; "I recommend that pro-
phylactic anticonvulsants not be started in this situation,
but would monitor and recommend them if a seizure
occurred"; "I discuss the benefits and risks of anticonvul-
sants with the patient and let him or her decide what to
do"; "other"; or "I do not encounter this clinical situa-
tion".
The final question asked practitioners if they would be
interested in participating in the process of reviewing the
guideline.
Statistical analysis
The data were analysed using the Statistical Package for
the Social Sciences, version 11.5 (SPSS). Frequencies of
response were tabulated for each question according to
the practitioners' disciplines. Missing responses were
excluded from the analysis. Crosstabulations were calcu-
lated to establish the characteristics of the practitioners
who did not want to participate in reviewing a guideline.
Results
Description of participant sample
Of the 197 surveys sent to practitioners, 122 were
returned (62%; 7 medical oncologists, 72 neurologists, 14
radiation oncologists, 27 surgeons, and 2 other). Return
rates ranged from 54% (medical oncologists) to 93%
(radiation oncologists). Practitioners who worked at
regional cancer centres had a slightly higher return rate
than practitioners who worked in community or private
medical offices (65% versus 60%).
Only nineteen of the practitioners (16%) indicated that
the development of a guideline on the use of prophylactic
anticonvulsants would not be relevant to their practice.
However, the majority of practitioners (80%) indicated
that less than one quarter of their clinical cases involved
decisions regarding prophylactic anticonvulsant drug use.
Neurologists and surgeons had a greater proportion of
their caseloads involving these decisions than did other
disciplines.
Published guidelines
Eleven (9%) of 116 practitioners indicated that they were
aware of existing guidelines. Eight of these cited the prac-
tice parameter on anticonvulsant prophylaxis published
in Neurology in 2000 by Glantz et al [7]. One respondent
referred to a 1993 review published by Agbi & Bernstein
in Canadian Family Physician that described seizure proph-
ylaxis for brain tumour patients [8].
Clinical scenarios
Use of peri-operative anticonvulsants
Of the 114 practitioners who responded to this item, 25
(22%) thought that peri-operative anticonvulsant medi-
cations were "always" indicated, 55 (48%) felt that peri-
operative anticonvulsant medications were "sometimes"
indicated, and the remaining 33 (30%) felt that peri-oper-
ative medications were "never" indicated.
Patient currently using anticonvulsants, undergoing surgery
As was the case above, there was variation in response to
this scenario: 33% of the practitioners indicated that they
would recommend this patient stay on anticonvulsants,
31% of the practitioners indicated that they would taper
and discontinue the anticonvulsants, and 20% of the
practitioners indicated that they would discuss the bene-BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/23
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fits and risks of the anticonvulsants and let the patient
decide what to do.
Patient not currently using anticonvulsants, not undergoing surgery
The most common response to the scenario describing a
patient not currently using prophylactic anticonvulsant
drugs was to recommend that prophylactic anticonvul-
sants not be started unless the patient had a seizure
(74%). Twelve percent of the respondents indicated that
they would recommend anticonvulsants in this situation.
The remaining 13% of respondents did not encounter the
situation (5%), would recommend another treatment not
listed (4%), or would discuss the benefits and risks and let
the patient decide (4%).
Practitioners' choice to review a draft guideline
Of the 122 practitioners who responded, 88 responded
that they would be interested in reviewing a draft version
of a guideline, and 25 practitioners indicated they would
not want to review a draft of the guideline (80% versus
20%). In comparison to those who indicated a willing-
ness to review a draft of the document, non-reviewers
were more apt to say that the topic was irrelevant (9% ver-
sus 40%, p < 0.001), were somewhat more likely to have
fewer than 25% of their clinical cases involving anticon-
vulsant drug use decisions (77% versus 84%, p=not signif-
icant), and were more likely to indicate that they did not
encounter patients represented in the clinical scenarios
described (for treatment of patients currently using anti-
convulsants, 8% versus 16%; for treatment of patients not
currently using anticonvulsants, 3% versus 12%. Note
that p-values are not reported because there are too few
respondents (<5) to calculate chi square in a 'do not
encounter' category). The greatest variation in response
between practitioners who wanted to review and those
who did not want to review was observed for the question
on when peri-operative medications were indicated.
Twenty-eight percent of the practitioners who wanted to
review responded that peri-operative anticonvulsants
were "always" necessary; none of the non-reviewers indi-
cated that peri-operative anticonvulsants were "always"
indicated (p < 0.001).
Discussion
The survey presented the practitioners with three situa-
tions where anticonvulsants in patients with brain
tumours may be appropriate: peri-operatively in patients
without seizures; postoperatively in patients currently
using anticonvulsants, and in patients not currently using
anticonvulsants and not undergoing surgery. In contrast
to the third scenario, the first two situations yielded con-
siderable variation in practitioner response. One limita-
tion of the findings presented is that they are based on
self-reported data rather than on an objective analysis of
clinical practice. Self-reporting may bias response tenden-
cies: practitioners may respond to questions in the way
that they think the researchers want them to answer or
they may have poor recall of their own practice [9,10].
Another possible limitation is the potential response bias.
The return rate was 62%, and it is possible that that the
non-responders have no variation in practice. Nonethe-
less, the potential limitations of the self-reported data and
response bias are unlikely to account for the considerable
variation reported.
By identifying the practice variations, the guideline can
address these variations so that the guideline will be appli-
cable to more practitioners, not just a subgroup of practi-
tioners performing what is assumed to be the most
common practice. It is important to recognize that varia-
tions in practice do not necessarily imply that there is an
explicitly wrong and right practice. Variations in practice
can be based on patients' needs, morbidity rates and vari-
ations in consumer preferences for different outcomes
[11]. The evidence, vis a vis, a guideline, will help deter-
mine if there is a "correct answer" or whether the variation
is appropriate.
The data gathered from the survey may serve as an impor-
tant baseline for comparing future self reports in order to
measure the degree of change that occurs as a guideline is
developed, documented, and implemented. The primary
purpose for conducting a practice survey such as this is to
gauge the level of interest in the clinical community. In
this case, the majority of clinicians (84%) supported the
development of a clinical practice guideline on the use of
anticonvulsants in patients with brain tumours because it
was relevant to their practice, and 80% volunteered to
serve as external reviewers for the guideline. This early
'buy-in' not only promotes the guideline process and
development but also provides a voice for clinicians and
may facilitate acceptance and implementation of the
eventual guideline recommendations. It will be interest-
ing to observe whether the practitioners who volunteered
to review the guideline, review the guideline when it is
complete (projected completion date is winter 2004).
The 25 practitioners who said they did not want to review
a guideline were more apt to report that the topic was not
relevant to their practice than were those who volunteered
to review a guideline (40% versus 9%). Nonetheless, the
topic was a priority for the majority of respondents.
Unfortunately, the survey did not ask practitioners why
they did not want to participate any further in the devel-
opment of the guideline. Collecting data on why practi-
tioners do not want to participate in the guideline process,
even in circumstances where the topic may be relevant to
a component of their clinical practice, could help guide-
line developers tailor the process in the future to encour-
age the participation of more practitioners. AnotherPublish with BioMed Central    and   every 
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possible question for future surveys could involve asking
the practitioners if there are any topics that they feel are
priorities.
Conclusions
The survey was designed to answer three questions: the
reported current practice in Ontario for the prophylactic
use of anticonvulsants as part of the treatment for brain
tumour patients, the need for a guideline on such a use of
anticonvulsants, and the involvement of practitioners in
the development of this guideline. The survey established
that there is some variation in the reported current prac-
tice of prophylactic anticonvulsant therapy for patients
with brain tumours. Whether there is an optimal practice
has yet to be determined. Practitioners do seem to feel that
a guideline on prophylactic anticonvulsant use is war-
ranted, and most practitioners would be interested in par-
ticipating in the guideline development process.
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